Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Biotech
Gossamer and Chiesi pull the plug on PAH drug collaboration
After signing a $486 million biobuck deal with Italian biopharma Chiesi in 2024, Gossamer Bio has ended the collaboration and licensing agreement.
Will Maddox
Jul 27, 2026 10:03am
United Therapeutics' phase 3 win tees up filing to challenge J&J
Mar 2, 2026 10:40am
GSK pays $950M for Canadian biotech with Winrevair-like PAH drug
Feb 25, 2026 4:28am
Gossamer Bio fails phase 3 pulmonary arterial hypertension trial
Feb 23, 2026 9:50am
Series B round of $125M will fund Diagonal's move into clinic
Jan 8, 2026 6:30am
Keros shakes up leadership structure to go all in on DMD drug
Aug 7, 2025 6:15am
